This provider's $27.3M in total Medicare payments ranks in the 96th percentile of Clinical Laboratory providers nationally.
This provider's billing patterns fall within normal ranges for their specialty.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2020 | $548.64 | $453.50 | 1.21x | $95.14 | $11.9M | 18.6K | 18.5K |
| 2021 | $490.11 | $457.45 | 1.07x | $32.66 | $15.4M | 21.2K | 21.1K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81411 | Test for detecting genes associated with heart disease | 4.1K | $5.6M | $1.4K | 1.18x |
| 81442 | Gene analysis (noonan syndrome) genomic sequence analysis | 2.1K | $4.6M | $2.1K | 1.03x |
| 81185 | Gene analysis (calcium voltage-gated channel subunit alpha1 a) of full sequence | 4.2K | $3.5M | $846.27 | 1.45x |
| 81439 | Test for detecting genes associated with inherited disease of heart muscle | 4.1K | $2.4M | $584.87 | 1.04x |
| 81238 | Gene analysis (coagulation factor ix) full sequence analysis | 4.0K | $2.3M | $581.20 | 1.03x |
| 81410 | Test for detecting genes associated with heart disease | 4.1K | $2.1M | $504.00 | 1.19x |
| 81408 | Molecular pathology procedure level 9 | 772 | $1.5M | $2.0K | 1.09x |
| 81286 | Gene analysis (frataxin) of full sequence | 4.7K | $1.3M | $274.75 | 1.06x |
| 81414 | Test for detecting genes associated with heart disease, duplication/deletion analysis panel, at least 2 genes | 1.4K | $800.7K | $584.90 | 1.00x |
| 81413 | Test for detecting genes associated with heart disease, genomic sequence analysis panel, at least 10 genes | 1.4K | $800.6K | $584.84 | 1.00x |
| 81407 | Molecular pathology procedure level 8 | 430 | $363.8K | $846.15 | 1.05x |
| 81162 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants | 101 | $184.1K | $1.8K | 1.10x |
| 81405 | Molecular pathology procedure level 6 | 577 | $164.3K | $284.72 | 1.29x |
| 81406 | Molecular pathology procedure level 7 | 572 | $161.7K | $282.74 | 1.30x |
| 81404 | Molecular pathology procedure level 5 | 565 | $143.1K | $253.28 | 1.34x |
| 81226 | Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants | 234 | $105.5K | $450.91 | 1.05x |
| 0032U | Gene analysis (catechol-o-methyltransferase) for c.472g>a (rs4680) variant | 577 | $100.9K | $174.81 | 1.10x |
| 81403 | Molecular pathology procedure level 4 | 532 | $98.5K | $185.12 | 1.27x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [s cerevisiae]) full sequence analysis | 136 | $91.9K | $675.41 | 1.15x |
| 81307 | Gene analysis (partner and localizer of brca2) full sequence analysis | 157 | $91.6K | $583.74 | 1.23x |
This provider submits charges 1.14 times higher than what Medicare actually pays.
A markup ratio of 1.14x means for every $100 Medicare pays, this provider initially charges $114. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in CO for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America | Englewood, CO | $139.3M | ⚠️ Flagged |
| Biodesix, Inc. | Boulder, CO | $52.6M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data